Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 5/2010

01.05.2010 | Inflammatory Disorders

Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease

verfasst von: Toshikatsu Kaburaki, Fumiyuki Araki, Mitsuko Takamoto, Kimiko Okinaga, Atsushi Yoshida, Jiro Numaga, Yujiro Fujino, Hidetoshi Kawashima

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent publications have suggested considerable improvements in the clinical outcomes of ocular Behcet’s disease (BD) patients. However, the long-term time course of clinical ocular features of BD in recent cases remains largely unknown. In this study, we investigated annual time-course changes of best-corrected visual acuity (BCVA) during ocular convalescent stages, as well as annual frequency of ocular attacks during the initial 10 years of follow-up in patients with BD.

Methods

We studied 75 eyes in 39 patients (31 men, eight women) with BD, who were referred to our hospital between 1980 and 1996 within 1 year after the initial ocular attack and followed them up continuously for more than 10 years. The clinical courses of BCVA at the ocular convalescent stage from the onset of ocular disease were retrospectively examined, and the numbers of ocular attacks per eye per year were determined.

Results

Mean BCVA was 0.59 at 1 year, 0.31 at 3 years, and 0.12 at 10 years from the onset of ocular disease, while the numbers of ocular attacks per eye were 4.1 ± 3.1 at 1 year, 2.2 ± 1.9 at 5 years, and 1.4 ± 1.8 at 10 years. Ocular attacks were still observed in 33 eyes (45%) of 21 patients (54%) with BD even after 10 years. Final BCVA in 42 eyes (56%) became lower than 0.5. The major reasons for poor visual prognosis were macular atrophy (41%) and chorioretinal atrophy (26%).

Conclusions

The decline of BVCA continued, and nearly half the patients still suffered from ocular attacks at 10 years after the onset of ocular BD.
Literatur
1.
Zurück zum Zitat Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T (1993) Recent epidemiological features of Behçet’s disease in Japan. In: Godeau P, Wechsler B (eds) Behçet’s disease. Excerpta Medica, Amsterdam, pp 145–151 Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T (1993) Recent epidemiological features of Behçet’s disease in Japan. In: Godeau P, Wechsler B (eds) Behçet’s disease. Excerpta Medica, Amsterdam, pp 145–151
2.
Zurück zum Zitat Mochizuki M, Akduman L, Nussenblatt RB (1996) Behçet disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. St. Louis, Mosby, pp 663–675 Mochizuki M, Akduman L, Nussenblatt RB (1996) Behçet disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. St. Louis, Mosby, pp 663–675
3.
Zurück zum Zitat Evereklioglu C (2005) Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 50:297–350CrossRefPubMed Evereklioglu C (2005) Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 50:297–350CrossRefPubMed
4.
Zurück zum Zitat Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed
5.
Zurück zum Zitat Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295–296CrossRefPubMed Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295–296CrossRefPubMed
6.
Zurück zum Zitat Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 46:1161–1164CrossRefPubMed Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 46:1161–1164CrossRefPubMed
7.
Zurück zum Zitat Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD. Behçet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–79PubMed Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD. Behçet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–79PubMed
8.
Zurück zum Zitat Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arch Ophthalmol 84:451–452PubMed Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arch Ophthalmol 84:451–452PubMed
9.
Zurück zum Zitat Benezra D, Cohen E (1986) Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70:589–592CrossRefPubMed Benezra D, Cohen E (1986) Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70:589–592CrossRefPubMed
10.
Zurück zum Zitat Mimura Y (1979) Immunopathological and clinical studies on ocular allergic diseases. J Jpn Ophthalmol Soc 83:1909–1975 Mimura Y (1979) Immunopathological and clinical studies on ocular allergic diseases. J Jpn Ophthalmol Soc 83:1909–1975
11.
Zurück zum Zitat Yuasa T (1991) The etiology and clinical statistics of Behçet’s disease. Ganka (Jpn J Clin Ophthalmol) 33:225–232 Yuasa T (1991) The etiology and clinical statistics of Behçet’s disease. Ganka (Jpn J Clin Ophthalmol) 33:225–232
12.
Zurück zum Zitat Miyake M, Sunagawa M, Okinami S (1997) Behçet’s disease characteristics more than 10 years after diagnosis. Folia Ophthalmol Jpn 48:707–712 Miyake M, Sunagawa M, Okinami S (1997) Behçet’s disease characteristics more than 10 years after diagnosis. Folia Ophthalmol Jpn 48:707–712
13.
Zurück zum Zitat Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111:810–815CrossRefPubMed Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111:810–815CrossRefPubMed
14.
Zurück zum Zitat Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M (2005) Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefe Arch Clin Exp Ophthalmol 243:1147–1152CrossRef Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M (2005) Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefe Arch Clin Exp Ophthalmol 243:1147–1152CrossRef
15.
Zurück zum Zitat Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
16.
Zurück zum Zitat Kaçmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Foster CS, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group (2008) Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836CrossRefPubMed Kaçmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Foster CS, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group (2008) Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836CrossRefPubMed
17.
Zurück zum Zitat Behçet’s Disease Research Committee of Japan (1997) The Revised Criteria and Manual of Treatments of Behçet’s disease. In: Report of Behçet Disease Research Comittee, Ministry of Health and Welfare of Japan, Tokyo, pp 22–29 Behçet’s Disease Research Committee of Japan (1997) The Revised Criteria and Manual of Treatments of Behçet’s disease. In: Report of Behçet Disease Research Comittee, Ministry of Health and Welfare of Japan, Tokyo, pp 22–29
18.
Zurück zum Zitat Hogan MJ, Kimura SJ, Thygeson P (1959) Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47(5, Part 2):155–170PubMed Hogan MJ, Kimura SJ, Thygeson P (1959) Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47(5, Part 2):155–170PubMed
19.
Zurück zum Zitat Demiroğlu H, Barişta I, Dündar S (1997) Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology 104:701–705PubMed Demiroğlu H, Barişta I, Dündar S (1997) Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology 104:701–705PubMed
Metadaten
Titel
Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease
verfasst von
Toshikatsu Kaburaki
Fumiyuki Araki
Mitsuko Takamoto
Kimiko Okinaga
Atsushi Yoshida
Jiro Numaga
Yujiro Fujino
Hidetoshi Kawashima
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 5/2010
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-009-1234-z

Weitere Artikel der Ausgabe 5/2010

Graefe's Archive for Clinical and Experimental Ophthalmology 5/2010 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.